InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development.
3D InSight™ Microtissues are gold-standard, pharma-validated, preclinical co-culture tissue models for efficacy and toxicology testing with unique uniformity, ease of use and biological functionality.
Microtissue types
Advantages
InSphero’s scientists have validated and optimized 3D-cell-based assays and endpoints for several applications within the drug discovery and development cycle, spanning applications from the early phases to post-market in vitro studies. When you purchase 3D InSight™ microtissues or services, you gain access to our proven protocols and experience with these certified applications.
Microtissue types
Advantages
3D InSight™ Liver Toxicology Testing is our offer for compound developers looking for highly predictive, reliable and fast-turnaround liver toxicology testing using the market leading, primary 3D liver model, our 3D InSight™ Liver Microtissues. By pooling compound samples from our large customer base into bi-weekly testing runs, InSphero can offer this service at highest quality, fast turnaround and at an attractive price point. Our board-certified toxicologists review every dataset carefully and provide valuable insights to you.
Service types
In vitro liver and pancreatic toxicity testing:
3D InSight™ Tumor Microtissues from Patient-Derived Xenografts (PDX) are custom, assay-ready 3D in vitro tumor models engineered to reflect complex tumor biology without the use of artificial matrices. Ideal for early stage cancer drug efficacy testing and screening applications, these advanced cancer models help bridge the gap between preclinical in-vitro studies and mouse PDX models for subsequent in vivo testing.
Advantages:
3D InSight™ Islet Microtissues are gold-standard, pharma-validated, preclinical co-culture pancreatic islet models for efficacy and toxicology testing with unique uniformity, ease of use and biological functionality. Re-aggregated using our proprietary technology from primary, isolated islets, this 3D model offers a unique uniformity.
Microtissue products and research services
Advantages
3D InSight™ Islet Microtissues are gold-standard, pharma-validated, preclinical co-culture pancreatic islet models for efficacy and toxicology testing with unique uniformity, ease of use and biological functionality. Re-aggregated using our proprietary technology from primary, isolated islets, this 3D model offers a unique uniformity.
Microtissue products and research services
Advantages
Our scientists have developed islet and liver disease models based on our innovative 3D cell-based technology platforms that closely mimic healthy and diseased human biology. Our fully validated and standardized assay-ready 3D disease models and wide-range of certified applications accelerate your diabetes and fibrosis/NASH drug discovery.
InSphero has not received any reviews.
InSphero has not received any endorsements.